Pharmabiz6h
Late-breaking data reinforce long-term benefits of Abbott's Amplatzer Amulet device for people with atrial fibrillation at risk of stroke
Abbott Park, Illinois Wednesday, November 20, 2024, 13:00 Hrs [IST] ...
BioWorld14h
No magic with Abbott’s Amulet compared to Watchman
Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...
FierceBiotech22h
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
MassDevice23h
Abbott reports positive Amplatzer Amulet data in head-to-head trial with Boston Scientific’s Watchman
Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.